Cardiovascular diseases have become a significant cause of morbidity in patients with human immunodeficiency virus (HIV) infection. Heart transplantation (HT) is a well-established treatment of end-stage heart failure (ESHF) and is performed in selected HIV-infected patients in developed countries. Few data are available on the prognosis of HIV-infected patients undergoing HT in the era of combined antiretroviral therapy (cART) because current evidence is limited to small retrospective cohorts, case series, and case reports. Many HT centers consider HIV infection to be a contraindication for HT; however, in the era of cART, HT recipients with HIV infection seem to achieve satisfactory outcomes without developing HIV-related events. Consequently, selected HIV-infected patients with ESHF who are taking effective cART should be considered candidates for HT. The present review provides epidemiological data on ESHF in HIV-infected patients from all published experience on HT in HIV-infected patients since the beginning of the epidemic. The practical management of these patients is discussed, with emphasis on the challenging issues that must be addressed in the pretransplant (including HIV criteria) and posttransplant periods. Finally, proposals are made for future management and research priorities.

An update on heart transplantation in human immunodeficiency virus–infected patients / Agüero, F.; Castel, M. A.; Cocchi, Stefania; Moreno, A.; Mestres, C. A.; Cervera, C.; Pérez Villa, F.; Tuset, M.; Cartañà, R.; Manzardo, C.; Guaraldi, Giovanni; Gatell, J. M.; Miró, J. M.. - In: AMERICAN JOURNAL OF TRANSPLANTATION. - ISSN 1600-6135. - STAMPA. - 16:1(2016), pp. 21-28. [10.1111/ajt.13496]

An update on heart transplantation in human immunodeficiency virus–infected patients

COCCHI, Stefania;GUARALDI, Giovanni;
2016

Abstract

Cardiovascular diseases have become a significant cause of morbidity in patients with human immunodeficiency virus (HIV) infection. Heart transplantation (HT) is a well-established treatment of end-stage heart failure (ESHF) and is performed in selected HIV-infected patients in developed countries. Few data are available on the prognosis of HIV-infected patients undergoing HT in the era of combined antiretroviral therapy (cART) because current evidence is limited to small retrospective cohorts, case series, and case reports. Many HT centers consider HIV infection to be a contraindication for HT; however, in the era of cART, HT recipients with HIV infection seem to achieve satisfactory outcomes without developing HIV-related events. Consequently, selected HIV-infected patients with ESHF who are taking effective cART should be considered candidates for HT. The present review provides epidemiological data on ESHF in HIV-infected patients from all published experience on HT in HIV-infected patients since the beginning of the epidemic. The practical management of these patients is discussed, with emphasis on the challenging issues that must be addressed in the pretransplant (including HIV criteria) and posttransplant periods. Finally, proposals are made for future management and research priorities.
2016
2-nov-2015
16
1
21
28
An update on heart transplantation in human immunodeficiency virus–infected patients / Agüero, F.; Castel, M. A.; Cocchi, Stefania; Moreno, A.; Mestres, C. A.; Cervera, C.; Pérez Villa, F.; Tuset, M.; Cartañà, R.; Manzardo, C.; Guaraldi, Giovanni; Gatell, J. M.; Miró, J. M.. - In: AMERICAN JOURNAL OF TRANSPLANTATION. - ISSN 1600-6135. - STAMPA. - 16:1(2016), pp. 21-28. [10.1111/ajt.13496]
Agüero, F.; Castel, M. A.; Cocchi, Stefania; Moreno, A.; Mestres, C. A.; Cervera, C.; Pérez Villa, F.; Tuset, M.; Cartañà, R.; Manzardo, C.; Guaraldi, Giovanni; Gatell, J. M.; Miró, J. M.
File in questo prodotto:
File Dimensione Formato  
An update.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 540.78 kB
Formato Adobe PDF
540.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1102433
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 29
social impact